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conscious dogs with atrial ﬁbrillation and on action potentials
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László Virág, András Varró, and István Baczkó
Abstract: Atrial ﬁbrillation (AF) is the most common sustained cardiac arrhythmia and a major cause of morbidity and
mortality. Traditional antiarrhythmic agents used for restoration of sinus rhythmhave limited efﬁcacy in long-termAF and they
may possess ventricular proarrhythmic adverse effects, especially in patients with structural heart disease. The acetylcholine
receptor-activated potassium channel (IK,ACh) represents an atrial selective target for future AFmanagement.We investigated the
effects of the IK,ACh blocker tertiapin-Q (TQ), a derivative of the honeybee toxin tertiapin, on chronic atrial tachypacing-induced
AF in conscious dogs, without the inﬂuence of anesthetics that modulate a number of cardiac ion channels. Action potentials
(APs) were recorded from right atrial trabeculae isolated from dogs with AF. TQ signiﬁcantly and dose-dependently reduced AF
incidence and AF episode duration, prolonged atrial effective refractory period, and prolonged AP duration. The reference drugs
propafenone and dofetilide, both used in the clinical management of AF, exerted similar effects against AF in vivo. Dofetilide
prolonged atrial AP duration, whereas propafenone increased atrial conduction time. TQ and propafenone did not affect the QT
interval, whereas dofetilide prolonged the QT interval. Our results show that inhibition of IK,ACh may represent a novel,
atrial-speciﬁc target for the management of AF in chronic AF.
Key words: atrial ﬁbrillation, conscious dog, IK,ACh, propafenone, tertiapin-Q.
Résumé : La ﬁbrillation auriculaire (FA) constitue l’arythmie cardiaque soutenue la plus courante et une cause majeure de
morbidité et de mortalité. Les antiarythmiques traditionnels utilisés pour rétablir le rythme sinusal ont une efﬁcacité limitée
dans la FA a` long terme, et ils pourraient être associés a` des effets indésirables favorisant les arythmies ventriculaires, particu-
lièrement chez les patients présentant une maladie cardiaque structurelle. Le canal potassique activé par le récepteur de
l’acétylcholine (IK,ACh) représente une cible auriculaire sélective pour la prise en charge future de la FA. Nous avons étudié les
effets de la tertiapine-Q (TQ), un bloqueur du canal IK,ACh dérivé de la tertiapine (toxine de l’abeille), sur la stimulation auriculaire
rapide chronique provoquée par la FA chez des chiens conscients, sans l’inﬂuence d’anesthésiques, qui peuvent moduler un
certain nombre de canaux ioniques cardiaques. Nous avons enregistré des potentiels d’action (PA) a` partir de trabécules
d’oreillettes droites isolées de chiens présentant une FA. De façon marquée et proportionnelle a` la dose, la TQ permettait de
réduire la fréquence et la durée des épisodes de FA, ainsi que de prolonger la période réfractaire effective et la durée du PA dans
l’oreillette. La propafénone et le dofétilide, deux médicaments de référence utilisés dans la prise en charge clinique de la FA,
exerçaient des effets similaires contre la FA in vivo. Le dofétilide entraînait une prolongation de la durée du PA, alors que la
propafénone entraînait une augmentation des temps de conduction dans l’oreillette. Le dofétilide entraînait une prolongation
de l’intervalle QT, alors que la TQ et la propafénone n’avaient aucun effet sur ce paramètre. Nos résultats montrent que
l’inhibition du canal IK,ACh pourrait représenter une nouvelle cible propre a` l’oreillette pour la prise en charge de la FA
chronique. [Traduit par la Rédaction]
Mots-clés : ﬁbrillation auriculaire, chien conscient, IK,ACh, propafénone, tertiapine-Q.
Introduction
Atrial ﬁbrillation (AF) is the most prevalent chronic arrhythmia
(Kannel et al. 1982), associated with increased morbidity and mor-
tality due to thromboembolic complications and concomitant
heart failure (Wolf et al. 1991; McManus et al. 2012). Its incidence
and prevalence is rapidly increasing with the aging of the popu-
lation and the number of caseswill probably double by 2060 in the
European Union (Krijthe et al. 2013). There is a great unmet need
for more efﬁcacious and safer pharmacological AF therapy, be-
cause drugs currently used for rhythm control (i) may signiﬁcantly
increase the risk for torsades de pointes arrhythmias due to their
ventricular electrophysiological effects (Taira et al. 2010); (ii) can
promote adverse vascular events (Connolly et al. 2011); (iii) can
exhibit reduced efﬁcacy in persistent AF (Vos et al. 1998); (iv) and
the most effective antiarrhythmic drug, amiodarone, has serious
extracardiac side effects when administered chronically (Vorperian
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et al. 1997; Santangeli et al. 2012). In addition, as part of the path-
ological electrical remodeling that occurs in AF, the expression of
a number of ion channels and exchangers is altered (Nattel et al.
2008), which can modify the arrhythmia substrate and increase
triggered activity resulting in AF to become self-sustaining
(Wijffels et al. 1995), and can signiﬁcantly alter potential drug
targets.
A potential approach to improve pharmacotherapy of AF is the
identiﬁcation of drug targets ideally expressed only in atrial tissue
(Ravens et al. 2013), because atrial selective ion channel modula-
tion would be devoid of ventricular proarrhythmic adverse ef-
fects. The Kv1.5 channel that conducts the ultrarapidly activating
outwardly rectiﬁer IKur represents such a target (Wang et al. 1993;
Gaborit et al. 2007; Ford and Milnes 2008), because its block pro-
longs the atrial action potential duration (APD) and effective re-
fractory period (ERP) (Amos et al. 1996). However, data regarding
changes in IKur expression are inconsistent in animal experimen-
tal models of AF and human studies (Yue et al. 1997; Bosch et al.
1999; Grammer et al. 2000), with some clinical studies showing
downregulation of the channel in patients with chronic AF
(Van Wagoner et al. 1997). Another target with relative atrial
selectivity is the acetylcholine receptor-activated inwardly rectify-
ing IK,ACh (Kir3.1/Kir3.4) (Cha et al. 2006; Ehrlich and Nattel 2009),
which is found in larger amounts in the atria than in the ventri-
cles (Krapivinsky et al. 1995). Importantly, in contrast to the fact
that IK,ACh downregulation was also observed in chronic AF
(Dobrev et al. 2001), a constitutively active component of IK,ACh
was detected in patients with persistent AF (Dobrev et al. 2005).
Therefore, IK,ACh block represents a promising target for the treat-
ment of AF. The selective inhibition of IK,ACh was shown to exhibit
beneﬁcial effects against AF in different animal models anesthe-
tized with a combination of isoﬂurane and thiopental (Hashimoto
et al. 2006; Yamamoto et al. 2014). However, thiopental and iso-
ﬂurane have well-known ion channel modulating properties.
Thiopental blocks ICa,L, IK1, and IKs (Carnes et al. 1997; Heath and
Terrar 1996; Morey et al. 1997; Pancrazio et al. 1993; Sakai et al.
1996) and isoﬂurane blocks ICa,L and IKs (Buljubasic et al. 1992;
Suzuki et al. 2003), modulatesmitochondrial calcium-activated K+
channels (Kinoshita et al. 2016). These different effects on cardiac
ion channels can profoundly inﬂuence the outcome of atrial and
ventricular arrhythmia studies depending on the anesthetic used,
including thiopental and isoﬂurane (Freeman et al. 1990; Napolitano
et al. 1996; Baczkó et al. 1997).
Therefore, the aim of the present study was to evaluate the
effect of the selective IK,ACh blocker tertiapin-Q (TQ), amore stable
derivative of the honeybee venom toxin tertiapin (Jin and Lu
1999), on atrial ERP and inducibility and duration of AF in a con-
scious canine model of chronic atrial tachypacing-induced AF, de-
void of any possible confounding ion channelmodulating effects of
intravenous and (or) volatile anesthetics. Also, we compared the ef-
fects of TQ to those of propafenone (class IC) and dofetilide (class III),
both antiarrhythmic agents that are clinically used for AF rhythm
control. Finally, for the ﬁrst time, cardiac cellular electrophysiologi-
cal effects of these compounds were compared in atrial trabeculae
isolated from dogs with chronic right atrial tachypacing-induced AF
using the conventional microelectrode technique.
Materials and methods
Ethical issues
The experiments complied with the Guide for the Care and Use of
Laboratory Animals (USA NIH publication No. 85–23, revised 1996).
The protocols had been approved by the Ethical Committee for
the Protection of Animals in Research of the University of Szeged,
Szeged, Hungary (I-74-5-2012), and by the Department of Animal
Health and Food Control of the Ministry of Agriculture (XIII/1211/
2012).
Chronic atrial tachypacing-induced AF in conscious dogs
Male Beagle dogs (n = 6) weighing 12–15 kg were used for the
experiments. The dogs were accommodated to experimental per-
sonnel and equipment, every day for a week before the start of the
studies. The pacemaker and pacemaker electrode implantation
procedureswere performed under ketamine (Richter Gedeon Ltd.,
Hungary; induction: 10 mg/kg, i.v., maintenance: 2 mg/kg, every
20 min) + xylazine (CP-Pharma Handelsges, Germany; induction:
1 mg/kg, maintenance: 0.2 mg/kg, every 20 min) anesthesia as
described previously (Baczkó et al. 2014). Brieﬂy, 2 bipolar pace-
maker electrodes (Synox SX 53-JBP and Synox SX 60/15-BP; Biotro-
nik Hungary Ltd., Hungary) were positioned into the right atrial
appendage and apex of the right ventricle, respectively, and the
electrodes were connected to pacemakers (Logos DS and Philos S;
Biotronik Hungary Ltd., Hungary) in subcutaneous pockets in the
neck area, followed by radiofrequency catheter ablation of the AV
node (Figs. 1A and 1B). The pacemakers were programmed by the
ICS 3000 Programmer (Biotronik Hungary Ltd., Hungary). Follow-
ing recovery from surgery (3–5 days), right atrial tachypacing was
started at 400 beats/min (Fig. 1C), maintained for 6–7 weeks before
the experiments to allow electrical remodeling of the atria (mon-
itored by the measurement of the right atrial effective refractory
period (AERP) every second day). The AERPs were measured at
basic cycle lengths (BCL) of 150 and 300 ms with a train of 10
stimuli (S1) followed by an extrastimulus (S2), with the AERP de-
ﬁned as the longest S1–S2 interval that did not produce a response.
On the day of the experiment, atrial pacing was stopped and
continuous recording of the electrocardiogram started using pre-
cordial leads and the AERP was measured. A control set (25 times)
of 10-second-long rapid atrial bursts (800 beats/min, at twice
threshold) were performed to induce AF in conscious dogs (Fig. 1D)
preceded by a bolus infusion of vehicle in 15 min. Following the
measurement of AERP, additional sets of atrial bursts were ap-
plied subsequent to either TQ (Tocris Bioscience, Bristol, UK;
18g/kg then 56g/kg), or dofetilide (Sigma–Aldrich, 25g/kg), or
propafenone (Rytmonorm, Mylan EPD Ltd., Hungary; 0.3 mg/kg
then 1 mg/kg) i.v. administration. At least 4 days were allowed for
washout between in vivo experiments with different compounds.
All intravenous infusions were performed using a programmable
infusion pump (Terufusion TE-3; Terumo Europe, Leuven, Bel-
gium). The ECG was recorded using precordial leads and was dig-
itized and stored on a computer for off-line analysis using National
Instruments data acquisition hardware (National Instruments,
Austin, Texas, USA) and SPEL Advanced Haemosys software (ver-
sion 3.2, MDE Heidelberg GmbH, Heidelberg, Germany). The inci-
dence of AF, the total duration of AF, and the average duration of
AF episodes were measured and calculated along with changes in
AERP and QT interval. QT intervals were measured on dogs with
pacemaker implantation before the 12th burst and were not cor-
rected for heart rate because QT measurements were made at the
heart rate set to 80 beats/min by the ventricular pacemaker. Ex-
periments were performed in freely moving conscious dogs so
that any effects of anesthetics on AERP and AF could be ruled out.
Action potential recordings from canine right atrial
trabeculae with the conventional microelectrode technique
The dogs from the in vivo AF studies were used 4 days following
their completion to allow washout of the last applied compound.
Following sedation (xylazine, 1 mg/kg, i.v., and ketamine, 10 mg/kg,
i.v.) and anesthesia (pentobarbital, Sigma–Aldrich, 30 mg/kg, i.v.),
the heart was rapidly removed through right lateral thoracotomy.
The hearts were immediately rinsed in oxygenated modiﬁed
Locke’s solution containing (in mmol/L): NaCl 128.3, KCl 4, CaCl2
1.8, MgCl2 0.42, NaHCO3 21.4, and glucose 10. The pH of this solu-
tion was set between 7.35 and 7.4 when saturated with the mix-
ture of 95% O2 and 5% CO2 at 37 °C. Isolated right atrial trabeculae
were obtained and individuallymounted in a tissue chamber with
a volume of 50 mL. The preparations were stimulated through a
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pair of platinum electrodes in contact with the preparation using
rectangular current pulses of 2 ms duration. The stimuli were
delivered at a constant BCL of 500 ms for at least 60 min allowing
the preparation to equilibrate before the measurements were initi-
ated. Transmembrane potentials were recorded using conventional
glass microelectrodes, ﬁlled with 3 mol/L KCl and having tip resis-
tances of 5–20 M, connected to the input of a high impedance
electrometer (type 309; MDE Heidelberg GmbH, Heidelberg, Ger-
many) that was coupled to a dual beamoscilloscope. The conduction
time, maximum diastolic potential, action potential amplitude, and
APDmeasured at 25%, 50%, and 90%of repolarization (APD25, APD50,
and APD90, respectively) were evaluated off-line using a custom
made software running on an IBM compatible computer equipped
with an ADA 3300 analogue-to-digital data acquisition board (Real
Time Devices Inc., State College, Pennsylvania, USA) having a max-
imum sampling frequency of 40 kHz. Stimulation with a constant
BCL of 500 ms was applied during the course of the experiments.
We aimed at maintaining the same impalement throughout each
experiment; however, in case the impalement became dislodged,
adjustment was performed and the experiment continued if AP
characteristics of the re-established impalement deviated less
than 5% from the previous measurement. Due to the contractility
of these preparations, some of the impalements had to be re-
peated, therefore the maximum upstroke velocity (vmax) of the
action potentials was not evaluated, and the conduction time was
used to assess class I activity in the manuscript.
Compounds
TQ (Tocris Bioscience, Bristol, UK) was dissolved in distilled wa-
ter for conventional microelectrode experiments (stock solution:
30 mol/L), and in saline for in vivo experiments. Dofetilide (Sigma–
Aldrich) was dissolved in DMSO to obtain a stock solution of
1 mmol/L for microelectrode experiments, and the stock solution
was diluted in saline for in vivo experiments. For microelectrode
experiments, propafenone (Sigma–Aldrich) was dissolved in DMSO
(stock solution: 10 mmol/L), and in in vivo experiments, propafenone
was applied using the commercially available 3.5 mg/mL ampule
(Rytmonorm, Mylan EPD Ltd., Hungary). Each stock solution was
diluted prior to the actual experiment.
Statistical analysis
All data are expressed as mean ± SEM. Statistical analysis was
carried out using ORIGIN 8.1 (Microcal Software, Northampton,
Massachusetts, USA). Differences between means were compared
by one-way ANOVA followed by Student’s t test. Data were consid-
ered statistically signiﬁcant when p < 0.05.
Results
Effects of the IK,ACh blocker TQ, the IKr blocker dofetilide,
and the INa blocker propafenone on right AERP in
conscious dogs
Before the commencement of right atrial tachypacing at 400 beats/
min, right AERPwas 117 ± 5.8 and 127 ± 6.4ms in conscious dogs (n = 6;
at basic cycle lengths of 150 and 300 ms, respectively). Rapid right
atrial pacing for 6–7 weeks markedly shortened right AERP, as
shown on panel B of Figs. 2, 3, and 4 (measured at the basic cycle
length of 300 ms). AERP was signiﬁcantly and dose-dependently
prolonged by TQ at both cycle lengths of 300 ms (Fig. 2B), and of
150 ms: 82.3 ± 1.48 ms in control vs. 93.3 ± 3.33 ms (n = 6, p < 0.05)
following 18 g/kg and 106.7 ± 2.11 ms (n = 6, p < 0.05) following
56 g/kg. The AERP was also signiﬁcantly prolonged by dofetilide
(Fig. 3B; at 150 ms BCL: 81.0 ± 1.81 ms in control vs. 98.3 ± 3.07 ms
(n = 6, p < 0.05) following 25 g/kg). Only the larger dose of
propafenone increased AERP at the BCL of 150 ms: 80.2 ± 0.98 ms
in control vs. 85.0 ± 2.89 ms (n = 6, p > 0.05) following 0.3 mg/kg
and 96.7 ± 3.33 ms (n = 6, p < 0.05) following 1 mg/kg, while the
AERP was signiﬁcantly increased by both propafenone doses at
the cycle length of 300 ms (Fig. 4B).
Effects of TQ, dofetilide, and propafenone on burst-induced
AF in conscious dogs
Rapid right atrial bursts at 800/min did not induce any AF in any
of the animals before the commencement of chronic right atrial
Fig. 1. Representative ECG recordings from a conscious dog (control) showing (A) sinus rhythm (heart rate = 75/min), (B) complete
atrioventricular block following radiofrequency catheter ablation (ventricular rate set to 50/min by ventricular pacemaker), (C) right atrial
(RA) tachypacing at 400/min, and (D) right atrial burst pacing (800/min) induced atrial ﬁbrillation. RV, right ventricular.
Pagination not final (cite DOI) / Pagination provisoire (citer le DOI)
Juhász et al. 3
Published by NRC Research Press
Ca
n.
 J.
 P
hy
sio
l. 
Ph
ar
m
ac
ol
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.n
rc
re
se
ar
ch
pr
es
s.c
om
 b
y 
D
r I
stv
an
 B
ac
zk
o 
on
 1
1/
10
/1
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
 
tachypacing. Infusion of the IK,ACh blocker TQ dose-dependently
and robustly reduced the incidence of right atrial burst-induced
AF (Fig. 2A), the total duration of AF (Fig. 2C), and the average
duration of AF episodes (Fig. 2D) in conscious dogs. The antiarrhyth-
mic effect of TQ was then compared with the class III compound
dofetilide and class IC drug propafenone, both used in clinical
settings for rhythm control in AF management. Both dofetilide
(Fig. 3A) and propafenone (Fig. 4A) reduced AF incidence, the total
duration of AF (Figs. 3C and 4C), and the average duration of AF
episodes (Figs. 3D and 4D). These results clearly show that TQ
exhibits marked antiarrhythmic effect against AF in conscious
dogs, and this effect seemed to be stronger than those of dofetilide
and propafenone.
Effects of TQ, dofetilide, and propafenone on the QT
interval in conscious dogs
Importantly, none of the investigated doses of TQ prolonged the
QT interval in conscious dogs, yielding 283.0 ± 10.36ms in control vs.
281.8 ± 13.29 ms (n = 6, p > 0.05) following 18 g/kg and 268.2 ±
17.75 ms (n = 6, p > 0.05) following 56 g/kg. Dofetilide (25 g/kg)
signiﬁcantly prolonged the QT interval in conscious dogs, from
265.8 ± 8.68 ms in control to 302.8 ± 10.53 ms (n = 6, p < 0.05).
Propafenone did not inﬂuence the duration of the QT interval:
268.0 ± 8.41 ms in control vs. 265.4 ± 9.34 ms (n = 6, p > 0.05)
following 0.3 mg/kg and 272.2 ± 7.70 ms (n = 6, p > 0.05) following
1 mg/kg.
Effects of TQ, dofetilide, and propafenone on action
potentials in atrial trabeculae isolated from dogs with AF
To evaluate changes in action potential parameters following
chronic atrial tachypacing, in preliminary experiments from non-
instrumented dogs in sinus rhythm, the following action potential
parameters were measured from right atrial trabeculae: conduc-
tion time, 4.4 ± 0.3 ms; action potential amplitude, 107.1 ± 1.6 mV;
diastolic potential, −87.9 ± 1.2 mV; APD25, 28.7 ± 2.0 ms; APD50,
64.5 ± 3.8 ms; APD90, 133.5 ± 5.4 ms (n = 12). These APD values in
non-instrumented dogs were signiﬁcantly longer at all investi-
gated percentages of repolarization than those following chronic
right atrial tachypacing (see APD values following chronic atrial
tachypacing as control in Fig. 5).
Right atrial trabeculae were isolated from the dogs used for the in
vivo AF studies, allowing washout of the last compound tested. The
effects of TQ (30 nmol/L), dofetilide (100 nmol/L), and propafenone
(1 mol/L) on the action potential conﬁguration and action poten-
tial parameters are shown in Fig. 5. All measurements were per-
formed at the cycle length of 500ms. TQ signiﬁcantly prolonged the
action potential at all percentages of repolarization (APD25, APD50,
and APD90) in right atrial trabeculae from dogs with AF (Fig. 5
bottom panel). TQ did not inﬂuence conduction time (4.6 ± 0.5 ms
in control vs. 4.6 ± 0.3 ms following TQ, n = 7, p > 0.05), action
potential amplitude (107.0 ± 1.4 mV in control vs. 107.0 ± 3.4 mV
following TQ, n = 7, p > 0.05), diastolic potential (−82.9 ± 1.1 mV in
control vs. −81.7 ± 1.2 mV following TQ, n = 7, p > 0.05). Dofetilide
signiﬁcantly prolonged the APD only at 90% of repolarization
(Fig. 5 bottom panel). Dofetilide did not alter conduction time
(3.7 ± 1.0 ms in control vs. 3.6 ± 0.9 ms following dofetilide, n = 4,
p > 0.05), action potential amplitude (109.8 ± 1.4 mV in control vs.
111.3 ± 0.8 mV following dofetilide, n = 4, p > 0.05), diastolic poten-
tial (−87.5 ± 3.4 mV in control vs. −88.3 ± 2.8 mV following dofeti-
lide, n = 4, p > 0.05). Propafenone did not prolong the atrial action
potential (Fig. 5 bottom panel), did not inﬂuence the action poten-
tial amplitude (101.4 ± 2.7 mV in control vs. 101.8 ± 2.2 mV following
propafenone, n = 5, p > 0.05) or diastolic potential (−83.1 ± 0.5 mV in
Fig. 2. Effect of tertiapin-Q (TQ; 18 and 56 g/kg, i.v.) administration on atrial tachypacing-induced experimental atrial ﬁbrillation (AF) in
conscious dogs. The data show that administration of both 18 and 56 g/kg TQ signiﬁcantly (A) reduced the incidence of AF, (B) increased the
atrial effective refractory period (AERP), and decreased (C) the total duration of AF and (D) the average duration of AF episodes in conscious
dogs. *p < 0.05; signiﬁcantly different from control values, one-way ANOVA, n = 6 animals. AERP shown in the ﬁgure was measured at the
basic cycle length of 300 ms. [Colour online.]
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control vs. −84.0 ± 1.5 mV following propafenone, n = 5, p > 0.05),
but signiﬁcantly increased conduction time (3.1 ± 0.3ms in control
vs. 3.9 ± 0.3 ms following propafenone, n = 5, p < 0.05).
Discussion
There is an unmet need for the safer and more efﬁcacious phar-
macological management of AF with compounds that lack ventricu-
lar cardiac electrophysiological (proarrhythmic) adverse effects. In
themajorityof invivo studies characterizingdrugcandidates against
AF, animals anesthetizedwith volatile and (or) intravenous anesthet-
icswereused. These anesthetic agents have their own relativelywell
identiﬁed effects on cardiac ion channels (Carnes et al. 1997;
Heath and Terrar 1996; Morey et al. 1997; Pancrazio et al. 1993;
Sakai et al. 1996) that can signiﬁcantly inﬂuence the results of
these antiarrhythmic studies (Freeman et al. 1990; Napolitano
et al. 1996). In this work, the effects of the atrial selective IK,ACh
inhibitor TQ on AF were investigated in freely moving, conscious
dogs, and the results were compared with those with dofetilide
and propafenone, drugs used in the clinical setting for rhythm
control in patients with AF. Also, for the ﬁrst time, the effects of
these compounds on atrial action potential conﬁguration and pa-
rameters were compared in right atrial trabeculae isolated from
dogs with chronic right atrial tachypacing-induced AF.
Rapid atrial pacing in dogs is an established large animal AF
model where tachypacing leads to electrical and structural re-
modeling in the atria (Morillo et al. 1995; Gaspo et al. 1997). In the
present study, the electrical remodeling was monitored as the
gradual decrease in AERP over the course of chronic tachypacing in
our animals. In our conscious in vivo canine AFmodel, TQmarkedly
and dose-dependently reduced the incidence of AF, the total and
average duration of AF episodes, and this effect was paralleled by a
signiﬁcantly increased right AERP following acute intravenous TQ
administration (Fig. 2). The signiﬁcant prolongation by TQ of the
APD at all percentages of repolarization was most likely responsi-
ble for the increased AERP in right atrial trabeculae isolated from
these animals (Fig. 5). TQ is a honeybee venom toxin peptide deriva-
tive (Jin and Lu 1999) that is a highly selective inhibitor of GIRK (Kir3)
channels carrying the acetylcholine-sensitive potassium current,
IK,ACh (Dascal et al. 1993; Ehrlich et al. 2004). This channel is acti-
vated via muscarinic receptors following vagal stimulation
(Yamada et al. 1998) leading to atrial action potential shortening
and increased atrial dispersion of repolarization (Liu and Nattel
1997), suggesting an important role for this channel in creating an
arrhythmia substrate for AF (Kovoor et al. 2001; Nattel 2002). Al-
though IK,ACh downregulation was found in AF patients (Brundel
et al. 2001; Dobrev et al. 2001), a constitutively active component
independent of muscarinic receptor activation was later identi-
ﬁed in patients with chronic AF (Dobrev et al. 2005). In a dogmodel
of atrial tachypacing-induced AF, constitutive IK,ACh was also ob-
served (Ehrlich et al. 2004). Inhibition of IK,ACh by TQ increased
atrial APD in atrial tachycardia-remodeled canine coronary-
perfused left atrial preparations and decreased atrial tachycardia
inducibility (Cha et al. 2006), similarly to the APD prolongation
observed in right atrial trabeculae and the in vivo antiarrhythmic
activity following TQ application in our study. IK,ACh inhibition
proved to be beneﬁcial in previous, other caninemodels of AF— like
aconitine and vagal nerve stimulation-induced AF (Hashimoto et al.
2006); however, in these studies, the effects of IK,ACh inhibition were
tested during isoﬂurane and (or) combined isoﬂurane + thiopental
anesthesia (Yamamoto et al. 2014). Thiopental signiﬁcantly pro-
longed AERP in a concentration-dependent manner and caused an
increase in atrial wavelength in guinea pig hearts (Napolitano
et al. 1996), and isoﬂurane was found to have antiﬁbrillatory ef-
fects in canine atria (Freeman et al. 1990). Although IK,ACh is also
present in the ventricles (Krapivinsky et al. 1995), it is important
to note that in conscious dogs, TQ did not prolong the QT interval
in this study, suggesting that selective IK,ACh block is unlikely to
provoke ventricular arrhythmias based on repolarization prolon-
gation. The lack of QT prolongation by TQ in this study is in
agreement with previous studies showing no signiﬁcant ventric-
ular effects following IK,ACh block (Machida et al. 2011).
The class IC antiarrhythmic drug propafenone and class III an-
tiarrhythmic compound dofetilide were chosen as reference mol-
ecules in this study; both compounds are used in the clinical
management of AF for rhythm control (Kirchhof et al. 2016; Piccini
and Fauchier 2016). Both propafenone and dofetilide reduced AF
incidence, decreased the duration of AF episodes, and increased
right atrial ERP in conscious dogs with right atrial tachypacing-
induced remodeling. Dofetilide prolonged the atrial APD while
propafenone increased atrial conduction time in right atrial trabec-
ulae isolated from dogs with AF. Dofetilide selectively blocks IKr in
the concentration used in this study (Jurkiewicz and Sanguinetti
1993), and its beneﬁcial effects in AF are based on prolongation of
atrial repolarization and AERP (Allessie et al. 2001; Pedersen et al.
2001; Singh et al. 2000). However, dofetilide signiﬁcantly prolongs
ventricular APD aswell thatmanifests asmarkedQT prolongation
on the ECG, and can provoke serious ventricular arrhythmias
(Wolbrette 2003; Lengyel et al. 2007). In the present study, dofeti-
lide signiﬁcantly prolonged the QT interval in conscious animals.
Propafenone is a class IC antiarrhythmic drug, exhibiting INa, beta-
adrenergic receptor and also HERG-blocking properties (Kohlhardt
and Seifert 1980; Stoschitzky et al. 2016; Mergenthaler et al. 2001),
and the drug is successfully applied for rhythm control in AF
management due to its conduction-slowing effects (Allessie et al.
2001; Kirchhof et al. 2016). Propafenone is not recommended in
patients with structural heart disease due to ventricular proarrhyth-
miaand increasedmortality (CAST Investigators 1989). Interestingly,
Fig. 3. Effect of the administration of the class III antiarrhythmic
dofetilide (25 g/kg, i.v.) on atrial tachypacing-induced experimental
atrial ﬁbrillation (AF) in conscious dogs. The data show that dofetilide
signiﬁcantly (A) reduced the incidence of AF, (B) prolonged the atrial
effective refractory period (AERP), and decreased (C) the total duration
of AF and (D) the average duration of AF episodes in conscious dogs.
*p < 0.05; signiﬁcantly different from control values, one-way ANOVA,
n = 6 animals. AERP shown in the ﬁgure was measured at the basic
cycle length of 300 ms. [Colour online.]
Pagination not final (cite DOI) / Pagination provisoire (citer le DOI)
Juhász et al. 5
Published by NRC Research Press
Ca
n.
 J.
 P
hy
sio
l. 
Ph
ar
m
ac
ol
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.n
rc
re
se
ar
ch
pr
es
s.c
om
 b
y 
D
r I
stv
an
 B
ac
zk
o 
on
 1
1/
10
/1
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
 
the applied dose and concentration of propafenone did not pro-
long the QT interval in conscious dogs and did not prolong APD in
isolated right atrial trabeculae (Fig. 5). Therefore, propafenone most
likely exerted its beneﬁcial effects against AF via mechanisms other
than HERG block in this study. The prolongation of repolariza-
tion and slowing of conduction would prevent or decrease
atrial reentry following the administration of dofetilide and
propafenone, respectively. Interestingly, both propafenone and
dofetilide were suggested to exert IK,ACh-blocking effects (Mori
et al. 1995; Voigt et al. 2010); however, it is not clear yet to what
Fig. 4. Effect of propafenone (0.3 and 1 mg/kg, i.v.) administration on right atrial tachypacing-induced experimental atrial ﬁbrillation (AF) in
conscious dogs. The data show that propafenone administration signiﬁcantly (A) reduced the incidence of AF, (B) increased the atrial effective
refractory period (AERP), and decreased (C) the total duration of AF and (D) the average duration of AF episodes (only the larger dose) in
conscious dogs. *p < 0.05; signiﬁcantly different from control values, one-way ANOVA, n = 6 animals. AERP shown in the ﬁgure was measured
at the basic cycle length of 300 ms. [Colour online.]
Fig. 5. Effects of tertiapin-Q (TQ; 30 nmol/L), dofetilide (100 nmol/L), and propafenone (1 mol/L) on action potential durations (APD) at 90%,
50%, and 25% of repolarization, measured in right atrial trabeculae isolated from dogs with AF. Top panel shows representative AP recordings
and bottom panel summarizes grouped data (n = 4–8/group). TQ prolonged APD measured at all % of repolarization. As expected, dofetilide
only prolonged APD90 and propafenone did not inﬂuence APD. The dotted line in the top panel represents 0 mV.
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degree these effects contribute to their beneﬁcial effects in pa-
tients with AF. Of note, neither dofetilide nor the class IC antiar-
rhythmic drug ﬂecainide had signiﬁcant effects against AF in dogs
anesthetized with the combination of thiopental and isoﬂurane
(Yamamoto et al. 2014), emphasizing again the need for experi-
ments in conscious animals.
Study limitations
The species differences regarding the relative roles of different
atrial ionic currents, including IK,ACh, in dogs and humans are not
yet fully explored. In dogs subjected to chronic atrial tachypacing,
a constitutive IK,ACh has been observed (Ehrlich et al. 2004) and a
constitutively active IK,ACh has also been identiﬁed in patients
with chronic AF (Dobrev et al. 2005), suggesting a potentially im-
portant role of IK,ACh in AF. However, the complex etiology, and
the heterogeneous mechanisms responsible for the initiation and
maintenance of AF in clinical settings, as opposed to chronic atrial
tachypacing in dogs should be considered. Based on the above, the
results obtained in the chronic atrial tachypacing-induced canine
experimental AF model should be extrapolated to human clinical
settings with caution and further studies are needed to evaluate
the role of IK,ACh block in patients with AF.
Conclusions
We found that the selective IK,ACh inhibitor TQ signiﬁcantly
decreased the incidence of AF, reduced the duration of AF epi-
sodes, and prolonged AERP in conscious dogs with chronic right
atrial tachypacing induced atrial remodeling. In this model, sim-
ilar effects on AF and AERP were observed following the adminis-
tration of the class IC antiarrhythmic drug propafenone, and the
class III compound dofetilide, both used in the clinical manage-
ment of AF. In right atrial trabeculae isolated from these dogs
with AF, atrial APDs were prolonged by TQ and dofetilide, but not
by propafenone, which increased atrial conduction time. Impor-
tantly, TQ did not affect the QT interval, suggesting that the ben-
eﬁcial effects against AF are not accompanied by adverse effects
on ventricular repolarization; therefore, selective IK,ACh inhibi-
tors may be promising atrial selective compounds in the future
management of AF.
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